Skip to Main Content

Author Details

Joan Albanell
Hospital del Mar Research Institute
1990
258
62
Timothy Clark (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
34810173Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain.Eur J Hosp Pharm2023
37714872The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.Sci Rep2023
38017230Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.Virchows Arch2023
37517596Characterization and spatial distribution of the immune cell infiltrate in triple-negative breast cancer: a novel classification based on plasma cells and CD8+ T cells.Hum Pathol2023
37500796Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer.Virchows Arch2023
37046799miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.Cancers (Basel)2023
36743520Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.Ther Adv Med Oncol2023
36899106Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells.Cell Death Differ2023
36239405Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.Oncologist2023
36165912Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.Clin Cancer Res2023
35301507LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.Nat Cancer2022
35348729mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.Mol Cancer Res2022
35594351Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.Sci Adv2022
35816382Exploring the Association of Cancer and Depression in Electronic Health Records: Combining Encoded Diagnosis and Mining Free-Text Clinical Notes.JMIR Cancer2022
36362083Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway.Int J Mol Sci2022
36085201Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.Nat Commun2022
35223459Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.Front Oncol2022
35329936CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer.J Clin Med2022
34902765Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).Eur J Cancer2022
32253118Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.Arch Bronconeumol (Engl Ed)2021
33809005Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients.Cancers (Basel)2021
34617955Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.JAMA Oncol2021
34385295Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.Clin Cancer Res2021
34580116CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function.Cancer Immunol Res2021
34183353Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.Cancer Discov2021
34204960The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models.Cancers (Basel)2021
34117028In Memoriam: José Baselga's Journey in Cancer Medicine.Clin Cancer Res2021
33298266Targeted metabolomics in formalin-fixed paraffin-embedded tissue specimens: Liquid chromatography-tandem mass spectrometry determination of acidic metabolites in cancer research.Talanta2021
32231712Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study.Ther Adv Med Oncol2020
31699826Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.Clin Cancer Res2020
31830538Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.Cancer Treat Rev2020
32573490FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.J Clin Invest2020
33014831MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma.Front Oncol2020
32365528The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.Cancers (Basel)2020
32304084Circulating Tumor Cells: Applications for Early Breast Cancer.Adv Exp Med Biol2020
32404410Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.Mol Cancer Ther2020
30523021NK Cell Infiltrates and HLA Class I Expression in Primary HER2<sup>+</sup> Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival.Clin Cancer Res2019
31388936Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.Breast Cancer Res Treat2019
31491604Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.Eur J Cancer2019
31484705HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.Mol Cancer Ther2019
31189644High Numbers of Circulating CD57<sup>+</sup> NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2<sup>+</sup> Primary Breast Cancer.Cancer Immunol Res2019
31303965Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.Oncotarget2019
30926829The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.Sci Rep2019
31015643Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities.Nat Rev Urol2019
31069160Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.Oncoimmunology2019
31069129Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.J Drug Assess2019
31090082SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.Prostate2019
31160383Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.Mol Cancer Res2019
27993109Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.Curr Med Chem2018
29916189Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.Clin Transl Oncol2018
  • 1 - 50 of 258

Recommended Authors

Chiara Corti
University of Milano
Career Start Year 2017
Number of shared co-authors 1
Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 10
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 10
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 6
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 3
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 3
Sara M Tolaney
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 7
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 11
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 6
Lissandra Dal Lago
Institut Jules Bordet
Career Start Year 2002
Number of shared co-authors 8
Matthew P Goetz
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 13
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 10
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 3
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 11
Carolien P Schr??der
University of Groningen, University Medical Center Groningen
Career Start Year 1995
Number of shared co-authors 8
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 5
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 11
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 2
Linda T Vahdat
Dartmouth Cancer Center
Career Start Year 1993
Number of shared co-authors 7
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 6
Vera J Suman
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 10
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 1
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 6
Alberto Zambelli
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 2
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Career Start Year 1986
Number of shared co-authors 14
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 7
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 3
Gabriel N Hortobagyi
The University of Texas MD Anderson Cancer Center
Career Start Year 1976
Number of shared co-authors 15
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 7
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 11

Collaborators

José Baselga
Co-authored papers 38
Antoni Ribas
University of California Los Angeles (university of california los angeles)
Co-authored papers 13
Daniel Prieto-Alhambra
University of Oxford
Co-authored papers 7
Jos?? Palacios
Universidad de Alcala
Co-authored papers 7
Abel Gonzalez-Perez
Universitat Pompeu Fabra
Co-authored papers 5
Jeffrey S Ross
Foundation Medicine
Co-authored papers 5
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Co-authored papers 5
Charles M Perou
Co-authored papers 4
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Co-authored papers 3
Anna Arnal-Estapé
Co-authored papers 3
Nuria Lopez-Bigas
Universitat Pompeu Fabra
Co-authored papers 3
Larry Norton
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 2
Laura I Furlong
Hospital del Mar Research Institute (IMIM), Pompeu Fabra University (UPF)
Co-authored papers 2
Giuseppe Curigliano
University of Milan
Co-authored papers 2
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 2
Victor E Reuter
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Susana Garcia-Recio
Co-authored papers 2
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
David Tamborero
Universitat Pompeu Fabra
Co-authored papers 2
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 2
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Co-authored papers 2
Miguel A Mayer
Hospital del Mar Medical Research Institute
Co-authored papers 2
Tomás Pascual
Co-authored papers 2
Ronald de Wit
Erasmus MC Cancer Institute
Co-authored papers 2
Elias Campo
Institute for Biomedical Research August Pi I Sunyer
Co-authored papers 2
Lisa A Carey
Co-authored papers 2
Hannah A Valantine
Co-authored papers 2
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 2
Jaime Ferrer
Health Research Institute Hospital La Fe
Co-authored papers 2
Release 1.2